Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579–89. https://doi.org/10.1016/S1470-2045(18)30608-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23(8):879–86. https://doi.org/10.1634/theoncologist.2018-0130

Article  PubMed  PubMed Central  Google Scholar 

Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6

Article  PubMed  PubMed Central  Google Scholar 

Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749–55. https://doi.org/10.1056/NEJMoa1609214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei SC, Meijers WC, Axelrod ML et al (2021) A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 11(3):614–625. https://doi.org/10.1158/2159-8290.CD-20-0856

Article  CAS  PubMed  Google Scholar 

Guha A, Al-Kindi S, Jain P et al (2020) Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use. Int J Cancer 147(6):1753–1754. https://doi.org/10.1002/ijc.32960

Article  CAS  PubMed  Google Scholar 

Escudier M, Cautela J, Malissen N et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136(21):2085–7. https://doi.org/10.1161/CIRCULATIONAHA.117.030571

Article  PubMed  Google Scholar 

Norwood TG, Westbrook BC, Johnson DB et al (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5(1):91. https://doi.org/10.1186/s40425-017-0296-4

Article  PubMed  PubMed Central  Google Scholar 

Puzanov I, Subramanian P, Yatsynovich YV et al (2021) Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer 9(6):e002553. https://doi.org/10.1136/jitc-2021-002553

Article  PubMed  PubMed Central  Google Scholar 

Lyon AR, López-Fernández T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehac244

Article  PubMed  Google Scholar 

D’Souza M, Nielsen D, Svane IM et al (2021) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 42(16):1621–31. https://doi.org/10.1093/eurheartj/ehaa884

Article  PubMed  Google Scholar 

Pollack A, Kontorovich AR, Fuster V et al (2015) Viral myocarditis–diagnosis, treatment options, and current controversies. Nat Rev Cardiol 12(11):670–80. https://doi.org/10.1038/nrcardio

Article  PubMed  Google Scholar 

Damluji AA, Forman DE, Wang TY et al (2023) Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation 147(3):e32–e62. https://doi.org/10.1161/CIR.0000000000001112

Article  PubMed  Google Scholar 

Dong M, Yu T, Tse G et al (2023) PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients. Curr Probl Cardiol 48(3):101527. https://doi.org/10.1016/j.cpcardiol.2022.101527

Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073–126. https://doi.org/10.1200/JCO.21.01440

Article  CAS  PubMed  Google Scholar 

Chen X, Jiang A, Zhang R et al (2022) Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med 9:882167. https://doi.org/10.3389/fcvm.2022.882167

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Gu X, Wang L et al (2022) The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 71(7):1693–1703. https://doi.org/10.1007/s00262-021-03115-y

Article  CAS  PubMed  Google Scholar 

Sarocchi M, Grossi F, Arboscello E et al (2018) Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist 23(8):936–42. https://doi.org/10.1634/theoncologist.2017-0452

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 71(16):1755–1764. https://doi.org/10.1016/j.jacc.2018.02.037

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamada N, Maeda A, Takase-Minegishi K et al (2021) Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol 12:803410. https://doi.org/10.3389/fimmu.2021.803410

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu JR, Florido R, Lipson EJ et al (2019) Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115(5):854–868. https://doi.org/10.1093/cvr/cvz026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spurr LF, Martinez CA, Kang W et al (2022) Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer 3(12):1498–512. https://doi.org/10.1038/s43018-022-00467-x

Article  CAS  PubMed  Google Scholar